Kangmei Pharma | 600518 - Current Liabilities


Kangmei Pharma reported CNY5.1B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Akebia Therapeutics USD 162.35M 1.48M Sep/2026
Alaunos Therapeutics USD 864K 269K Jun/2026
Avita Medical AUD 68.71M 6.04M Jun/2026
Cspc Pharmaceutical CNY 10.18B 65.36M Dec/2025
Dianthus Therapeutics USD 28.51M 5.87M Sep/2026
Genomma Lab Internacional MXN 5.67B 3.72B Sep/2026
Hypermarcas BRL 3.86B 659.6M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
IQVIA Holdings USD 7.78B 1.04B Sep/2026
Jiangsu Hengrui CNY 6.9B 2.65B Sep/2026
Kangmei Pharma CNY 5.1B 280.48M Jun/2026
Moderna USD 2.03B 506M Sep/2026
Organon & Co USD 2.65B 36M Sep/2026
Revvity USD 701.48M 574.88M Sep/2026
Sh Fosun Pharma CNY 35.3B 3.29B Sep/2026
Tectonic Therapeutic USD 10.37M 2.59M Jun/2026
Viatris USD 6.64B 290.7M Sep/2026
Wuxi Apptec CNY 23.85B 4.94B Sep/2026
Xeris Pharmaceuticals USD 134.48M 55.09M Sep/2026
Zz Pientze Pharmaceu CNY 2.74B 277.02M Sep/2026